Over time, researchers discovered that the appetite-suppressing and weight-loss effects of GLP-1 receptor agonists had broader applications, including the treatment of obesity and obesity-related conditions such as OSA
Keep vials protected from light, in their original packaging or wrapped in foil
A practical protocol: wake, inject AOD-9604, wait 20 minutes, perform 30-45 minutes of moderate cardio, then eat breakfast
The company also became profitable with its net income reaching $126 million in 2024, compared with a loss of $18 million in 2020
Orforglipron: First Oral Non-Peptide GLP-1 Agonist Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist with a molecular weight of 541.65 Da, developed by Eli Lilly